Page last updated: 2024-11-05

nandrolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nandrolone: C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

nandrolone : A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9904
CHEMBL ID757
CHEBI ID7466
SCHEMBL ID20140
MeSH IDM0014452

Synonyms (120)

Synonym
AC-15207
17beta-hydroxyestr-4-en-3-one
17beta-hydroxy-19-nor-4-androsten-3-one
17beta-hydroxy-4-estren-3-one
CHEBI:7466 ,
4-estren-17beta-ol-3-one
(17beta)-17-hydroxyestr-4-en-3-one
norandrostenolon
nandrolon
oestrenolon
nortestonate
menidrabol
norandrostenolone
19-nortestosterone
19-norandrostenolone
nsc-3351
u 2410
nortestosteronum
hsdb 3368
17-beta-hydroestr-4-en-3-one
einecs 207-101-0
nandrolonum [inn-latin]
estr-4-en-3-one, 17-hydroxy-, (17-beta)-
nortestosterone
estr-4-en-3-one, 17beta-hydroxy-
nandrolona [inn-spanish]
nsc 3351
(17-beta)-17-hydroxyestr-4-en-3-one
estr-4-en-3-one, 17-hydroxy-, (17beta)-
estr-4-en-3-one, 17-beta-hydroxy-
C07254
nandrolone
434-22-0
NCGC00159416-02
cpd000058610
NCGC00164479-01
19-nortestosterone, >=99.0% (hplc)
HMS2051I04
bdbm50080092
CHEMBL757 ,
nandrolone ciii
(8r,9s,10r,13s,14s,17s)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one
MLS002222325
smr000058610
D08250
decadura (tn)
nandrolone (inn)
LMST02010044
NCGC00159416-03
HMS2098E05
cas-434-22-0
tox21_201212
dtxcid403350
tox21_113167
tox21_113199
dtxsid7023350 ,
NCGC00258764-01
MLS001423989
HMS2272P06
CCG-100835
CS-1416
nandrolone [inn:ban]
nandrolonum
6pg9vr430d ,
ec 207-101-0
nandrolona
unii-6pg9vr430d
(+)-19-nortestosterone
4-estren-3-one-17.beta.-ol
nandrolone [mart.]
decadura
biobol
nandrolone [inn]
nandrolone [mi]
17-hydroxyestr-4-en-3-one
nandrolone [who-dd]
nandrolone ciii [usp-rs]
nandrolone [vandf]
nandrolone [hsdb]
nandrolone decanoate impurity d [ep impurity]
4-estren-17.beta.-ol-3-one
AKOS015894933
deca-durabolin (decanoate ester)
durabolin (phenylpropionate ester)
gtpl6949
HY-17432
NC00085
SCHEMBL20140
NCGC00159416-04
tox21_113167_1
19-nor-testosterone
(8r,9s,10r,13s,14s,17s)-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3h-cyclopenta[a]phenanthren-3-one
W-106227
estr-4-en-3-one, 17-hydroxy-, (17b)-
nandrolone, british pharmacopoeia (bp) reference standard
estr-4-en-3-one, 17-hydroxy-, (17.beta.)-
17.beta.-nortestosterone
17.beta.-nandrolone
AC-30575
sr-01000781257
SR-01000781257-3
(1s,2r,10r,11s,14s,15s)-14-hydroxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one
GS-6819
nandrolone, united states pharmacopeia (usp) reference standard
nandrolone, vetranal(tm), analytical standard
nandrolone decanoic acid
nandrolone base
6vw ,
(8~{r},9~{s},10~{r},13~{s},14~{s},17~{s})-13-methyl-17-oxidanyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1~{h}-cyclopenta[a]phenanthren-3-one
nandrolone 1.0 mg/ml in acetonitrile
HMS3715E05
DB13169
enta[a]phenanthren-3-one
(8~{r},9~{s},10~{r},13~{s},14~{s},17~{s})-13-methyl-17-oxidanyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1~{h}-cyclop
nandrolone, beta
nandrolone, alpha
Q421709
(8r,10r,13s,17s)-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one
nandrolone(19-nortestosterone)
nandrolone, 1mg/ml in methanol

Research Excerpts

Overview

Nandrolone decanoate is an anabolic-androgenic steroid that is frequently used at a very high dose to improve the physical performance. It is an androgenic-anabolic steroid with diverse medical applications but taken indiscriminately by some to rapidly increase muscle mass.

ExcerptReferenceRelevance
"Nandrolone is a testosterone analogue with anabolic properties commonly abused worldwide, recently utilized also as therapeutic agent in chronic diseases, cancer included. "( Nandrolone induces a stem cell-like phenotype in human hepatocarcinoma-derived cell line inhibiting mitochondrial respiratory activity.
Agriesti, F; Capitanio, N; Cela, O; Laurenzana, I; Mazzoccoli, C; Pacelli, C; Piccoli, C; Pomara, C; Ruggieri, V; Salerno, M; Sani, G; Scrima, R; Sessa, F; Tataranni, T, 2020
)
3.44
"Nandrolone decanoate is an anabolic-androgenic steroid that is frequently used at a very high dose to improve the physical performance. "( Reversal of the hepatic damage induced by the supraphysiological dose of nandrolone decanoate after its withdrawal in the adult male rat.
Bahey, NG; Shalaby, AM, 2018
)
2.16
"Nandrolone is an anabolic-androgenic steroid (AAS) that is highly abused by individuals seeking enhanced physical strength or body appearance. "( Anabolic-androgenic steroid treatment induces behavioral disinhibition and downregulation of serotonin receptor messenger RNA in the prefrontal cortex and amygdala of male mice.
Ambar, G; Chiavegatto, S, 2009
)
1.8
"Nandrolone is an anabolic steroid that has been demonstrated to reduce the loss of bone and muscle from hindlimb unweighting and to slow muscle atrophy after nerve transection. "( Nandrolone slows hindlimb bone loss in a rat model of bone loss due to denervation.
Bauman, WA; Cardozo, CP; Liu, X; Pan, J; Peng, Y; Qin, W; Sun, L; Wu, Y; Zaidi, M, 2010
)
3.25
"Nandrolone is an androgenic-anabolic steroid (AAS) with diverse medical applications but taken indiscriminately by some to rapidly increase muscle mass. "( Nandrolone androgenic hormone presents genotoxic effects in different cells of mice.
do Carmo, CA; Gonçalves, ÁL; Maistro, EL; Salvadori, DM, 2012
)
3.26
"Nandrolone is an anabolic steroid widely used in several sports. "( Effects of high-intensity exercises on 13C-nandrolone excretion in trained athletes.
Avois, L; Baume, N; Cauderay, M; Dvorak, J; Mangin, P; Saugy, M; Sottas, PE, 2005
)
2.03

Effects

Nandrolone decanoate has no effect on the SRE, VO2max and VO2submax of untrained rats. It has beneficial effects on weight, lean body mass and quality of life in selected patients with mild to moderate HIV wasting.

ExcerptReferenceRelevance
"Nandrolone has minimal effects on aggression, unless preceded by attack training."( Impact of anabolic androgenic steroids on adolescent males.
Lumia, AR; McGinnis, MY, 2010
)
1.08
"Nandrolone decanoate has no effect on the SRE, VO2max and VO2submax of untrained rats. "( Effects of nandrolone decanoate on VO2max, running economy, and endurance in rats.
Boyadjiev, NP; Georgieva, KN, 2004
)
2.16
"Nandrolone decanoate has beneficial effects on weight, lean body mass and quality of life in selected patients who have mild to moderate HIV wasting."( Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection.
Allen, BJ; Bodsworth, NJ; Finlayson, R; Furner, VL; Gold, J; High, HA; Li, Y; Michelmore, H; Oliver, CJ, 1996
)
2.05
"Once nandrolone has been metabolised, two major metabolites are excreted in urine, 19-norandrosterone (NA) and 19-noretiocholanolone (NE)."( Detection of nandrolone metabolites in urine after a football game in professional and amateur players: a Bayesian comparison.
Ayotte, C; Dvorak, J; Mangin, P; Robinson, N; Saugy, M; Taroni, F, 2001
)
1.14

Actions

ExcerptReferenceRelevance
"Nandrolone was shown to increase seizure rate when given in high (20mg twice weekly) intermittent doses."( The effects of nandrolone decanoate on cocaine-induced kindling in male rats.
Davis, WM; Long, SF; Wilson, MC, 2000
)
1.38

Treatment

Nandrolone decanoate treatment thus affects Ca (2+) uptake by the SR in a fibre-type dependent manner. The nandrol one treatment caused a 50% reduction of kidney alpha(1B)-adrenoceptors in rats.

ExcerptReferenceRelevance
"Nandrolone treatment (10-10 M) caused a time-dependent and concentration-dependent downregulation of mu opioid receptor (MOPr) transcripts in SH-SY5Y human neuroblastoma cells."( Nandrolone decreases mu opioid receptor expression in SH-SY5Y human neuroblastoma cells.
Guarino, G; Spampinato, S, 2008
)
2.51
"Nandrolone decanoate treatment increased MAP (CON=99+/- 1 mmHg; DECA=109+/-2 mmHg; p<0.01) but did not change the mean basal HR (CON=356+/-13 bpm; DECA=367+/-11 bpm)."( Long-term treatment with supraphysiological doses of nandrolone decanoate reduces the sensitivity of Bezold-Jarisch reflex control of heart rate and blood pressure.
Abreu, GR; Bissoli, NS; Busato, VC; de Andrade, TU; Jarske, RD; Medeiros, AR; Moysés, MR; Santos, MC, 2009
)
1.32
"Nandrolone treatment reduced the frequency of small fibers at 7 and 21 d after venom administration, and increased the frequency of large fibers at 7 d postinjury."( Nandrolone stimulates MyoD expression during muscle regeneration in the condition of myonecrosis induced by Bothrops jararacussu venom poisoning.
Gallacci, M; Garrido Cavalcante, WL; Gonçalves, W; Pai-Silva, MD; Wagner Alves de Souza, R, 2010
)
2.52
"Nandrolone decanoate treatment increased the QTc interval and reduced the parasympathetic indexes of HRV (RMSSD, pNN5 and high-frequency power) in sedentary and trained rats. "( The blockade of angiotensin AT1 and aldosterone receptors protects rats from synthetic androgen-induced cardiac autonomic dysfunction.
da H Silva, A; dos Santos, MC; Ferraz, EF; Marques Neto, SR; Nascimento, JH, 2013
)
1.83
"Nandrolone decanoate pre-treatment of suspended animals (nandrolone decanoate hindlimb-unweighted vs."( Nandrolone decanoate pre-treatment attenuates unweighting-induced functional changes in rat soleus muscle.
Bigard, X; Bouhlel, A; Joumaa, WH; Léoty, C, 2002
)
2.48
"Nandrolone treatments increased the acute hypothermic effects of morphine without modifying its acute antinociceptive and locomotor effects."( Effects of nandrolone on acute morphine responses, tolerance and dependence in mice.
Castañé, A; Célérier, E; Ghozland, S; Maldonado, R; Nyberg, F; Yazdi, MT, 2003
)
1.43
"Nandrolone decanoate treatment thus affects Ca (2+) uptake by the SR in a fibre-type dependent manner."( Nandrolone decanoate treatment affects sarcoplasmic reticulum Ca(2+) ATPase function in skinned rat slow- and fast-twitch fibres.
Bouhlel, A; Joumaa, WH; Léoty, C, 2003
)
2.48
"The nandrolone treatment caused a 50% reduction of kidney alpha(1B)-adrenoceptors (from 15 fmol/mg protein in control rats to 6.5 fmol/mg protein in treated rats)."( Nandrolone treatment decreases the level of rat kidney alpha(1B)-adrenoceptors.
Kindlundh, A; Lindblom, J; Mugisha, P; Nyberg, F; Uhlén, S, 2003
)
2.24
"Nandrolone treatment significantly reduced vocalizations and scent marking, and testosterone had no significant effect on behavior."( Long-term effects of pubertal anabolic-androgenic steroid exposure on reproductive and aggressive behaviors in male rats.
Farrell, SF; McGinnis, MY, 2004
)
1.04
"Nandrolone treatment was associated with greater improvements in perception of health than rhGH and sexual function than placebo."( A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment.
Beck, K; Bhasin, S; Geurts, P; Harms, MK; Mac, P; Padero, M; Sattler, F; Schroeder, ET; Singh, AB; Storer, TW; Willemsen, A; Woodhouse, LJ; Yarasheski, KE, 2005
)
1.31
"Nandrolone treatment decreases the level of rat kidney alpha1B-adrenoceptors."( Nandrolone treatment decreases the alpha1B-adrenoceptor mRNA level in rat kidney, but not the density of alpha1B-adrenoceptors in cultured MDCK-D1 kidney cells.
Hallberg, M; Lindblom, J; Magnusson, K; Nyberg, F; Petrovska, R; Uhlén, S, 2005
)
2.49
"Both nandrolone treatments did not modify the acute antinociceptive, hypothermic and hypolocomotor effects of THC or the development of tolerance after chronic THC administration."( Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence.
Ahdepil, T; Berrendero, F; Célérier, E; Maldonado, R; Nyberg, F; Wikander, H, 2006
)
1.05
"Nandrolone decanoate treatment resulted in greater increases in fat-free mass than placebo and demonstrated a trend for a significant increase when compared with testosterone."( Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting.
Aiuti, F; Batterham, MJ; Bloch, M; Danner, SA; Falleiros Carvalho, LH; Gatell, J; Gazzard, B; Geurts, TB; Gold, J; Harms, MK; Helmyr, PM; Horban, A; Lee, C; Panos, G; Phanuphak, P; Pinchera, A; Prasithsirikul, W; Rekers, H; Silva de Mendonça, J, 2006
)
1.45
"The nandrolone-treated patients showed significantly better maintenance of hemoglobin concentrations and body weight, and a highly significant reduction in number of blood transfusions."( Beneficial effects of an anabolic steroid during cytotoxic chemotherapy for metastatic cancer.
Allar, MJ; DeVita, SF; Richards, S; Sedransk, N; Spiers, AS, 1981
)
0.74
"Nandrolone-treated animals had similar serum estradiol levels as the sham animals, presumably due to conversion of endogenous or exogenous androgens."( The androgenic anabolic steroid nandrolone decanoate prevents osteopenia and inhibits bone turnover in ovariectomized cynomolgus monkeys.
Carlson, CS; Guidry, M; Jerome, CP; Obasanjo, IO; Power, RA; Register, TC; Weaver, DS, 1997
)
1.3
"Nandrolone treatment was moderately uterotropic in all treated versus ovariectomized animals. "( Nandrolone decanoate causes pathologic changes in the uterus of surgically postmenopausal female cynomolgus macaques.
Cline, JM; Obasanjo, IO; Schmotzer, S; Weaver, DS, 1998
)
3.19
"When nandrolone-pretreated rats were given acute EAMG by passive transfer of mAb 35 a paradoxical effect was seen."( Effects of the rate of acetylcholine receptor synthesis on the severity of experimental autoimmune myasthenia gravis.
Daha, MR; De Baets, MH; van Breda Vriesman, PJ; Verschuuren, J, 1988
)
0.73
"Treatment with nandrolone was initiated in adolescent (6-week-old) and young adult (10-week-old) rats."( Adolescence as a critical period for nandrolone-induced muscular strength in relation to abuse liability, alone and in conjunction with morphine, using accumbal dopamine efflux in freely moving rats.
Aono, Y; Kawashima, H; Saigusa, T; Shimba, S; Waddington, JL, 2023
)
1.52
"Pretreatment with nandrolone decanoate prevented such depression in tumor-bearing mice and increased MPS activities of normal or tumor-bearing mice above the level of non-treated normal mice."( Restorative effects of nandrolone decanoate on the mononuclear phagocyte system in tumor-bearing mice.
Nomoto, K; Ohhara, R; Sanui, H; Takeya, K; Yoshida, S, 1981
)
0.9
"Treatment with nandrolone for 6 months resulted in a significant increase in LBM associated with functional improvement in patients undergoing dialysis."( Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial.
Johansen, KL; Mulligan, K; Schambelan, M, 1999
)
0.98
"Treatment with nandrolone decanoate was found to restore the loss in carbonate, where the resulting mineral had a larger quantity of type B carbonate."( Characterization of bone mineral composition in the proximal tibia of cynomolgus monkeys: effect of ovariectomy and nandrolone decanoate treatment.
Carlson, CS; Chance, MR; Huang, RY; Miller, LM, 2002
)
0.86
"Rats treated with nandrolone showed a 48 +/- 1.7% loss of AChR compared to a loss of 58 +/- 3.6% in the control rats, suggesting enhanced AChR synthesis."( Effects of the rate of acetylcholine receptor synthesis on the severity of experimental autoimmune myasthenia gravis.
Daha, MR; De Baets, MH; van Breda Vriesman, PJ; Verschuuren, J, 1988
)
0.6

Toxicity

Pre-treatment with the anabolic steroid nandrolone decanoate (ND) increases the LD50 of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 5-Fluorouracil (FU) in NMRI mice. Study proposes that nandrole could be used in safe and effective way to combat hypercatabolic impact in burn injury.

ExcerptReferenceRelevance
"STS 557 was tested for adverse effects in mice by prenatal and postnatal investigations."( Prenatal toxic effects of STS 557. I. Investigations in mice.
Klaus, S, 1983
)
0.27
" Neither clinical, functional nor morphological investigations revealed toxic side effects of the drugs on the liver, the kidneys, the bone marrow, or on blood clotting function."( Toxicity of the progestagen STS 557 compared to levonorgestrel in beagles after oral administration for 6 months.
Güttner, J; Hillesheim, HG; Hoffmann, H; Oettel, M, 1982
)
0.26
"Pre-treatment with the anabolic steroid nandrolone decanoate (ND) increases the LD50 of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 5-Fluorouracil (FU) in NMRI mice."( Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours.
Bibby, MC; Double, JA; Mughal, MA, 1981
)
0.92
" No adverse effect of anabolic steroid administration was evident."( The effect of anabolic steroids on ameliorating the adverse effects of chronic corticosteroids on intestinal anastomotic healing in rabbits.
Buchmiller, TL; Fonkalsrud, EW; Kim, CS; Phillips, JD, 1993
)
0.29
" The purpose of this study was to determine and compare the direct toxic effects of commonly abused AAS (both 17 alpha-alkylated and nonalkylated) in primary hepatic cell cultures."( Toxic effects of anabolic-androgenic steroids in primary rat hepatic cell cultures.
Melchert, RB; Robertson, JW; Welder, AA, 1995
)
0.29
"Continuous combined estrogen-progestin therapy with Climodien is effective, safe and well tolerated in postmenopausal women, with a profile and incidence of adverse events consistent with those of existing HRT preparations."( Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints.
Gräser, T; Janaud, A; Römer, T; Wiedey, KD, 2001
)
0.31
" The incidences of adverse events were similar in all groups."( Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women.
Gräser, T; Koytchev, R; Müller, A; Oettel, M, 2000
)
0.31
" Overall, the profiles of adverse events recorded in clinical use were similar in the two preparations, whilst the safety profile of E2V/DNG in the large-scale study was similar to that of other HRT preparations and gave no cause for clinical concern."( Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment.
von Schoultz, B, 2003
)
0.32
" The high doses misused are associated with numerous adverse effects."( Impact of nandrolone decanoate on gene expression in endocrine systems related to the adverse effects of anabolic androgenic steroids.
Alsiö, J; Bergström, L; Birgner, C; Björkblom, L; Isaksson, P; Lindblom, J; Schiöth, HB, 2009
)
0.76
" Both dienogest doses were generally well tolerated, with low rates of treatment discontinuation due to adverse events."( A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis.
Faustmann, TA; Gerlinger, C; Köhler, G; Mueck, AO; Seitz, C, 2010
)
0.36
" Treatment-related adverse events (considered at least possibly treatment-related) occurred in 19."( Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial.
Bitzer, J; Machlitt, A; Palacios, S; Parke, S; Römer, T; Wildt, L, 2010
)
0.36
" Data were documented on volunteer diaries, and adverse events (AEs) were reported during five visits."( Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy.
Kuhl, H; Lange, E; Manthey, T; Mellinger, U; Mittmann, K; Palombo-Kinne, E; Sänger, N; Stahlberg, S; Wiegratz, I, 2011
)
0.37
" Treatment-related adverse events (AEs) occurred in 51."( Efficacy and safety of a combined oral contraceptive containing estradiol valerate/dienogest: results from a clinical study conducted in North America.
Mellinger, U; Nelson, A; Parke, S; Schmidt, A; Zampaglione, E, 2014
)
0.4
" During continuation of DNG, the recurrence rate of ovarian endometrioma on ultrasound, adverse events, changes in menstrual pattern, and pain score (visual analogue scale) were analyzed."( Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma.
Cho, S; Kim, SH; Lee, DY; Lee, SR; Seo, SK; Song, JY; Yi, KW, 2018
)
0.48
" We assessed the pelvic pain score and quality-of-life (QOL) score before and after taking dienogest as well as the prevalence of short-term (≤12 weeks) and long-term adverse effects (>52 weeks)."( Symptom-alleviating effect and adverse effect of dienogest in Korean women with endometriosis.
Jee, BC; Jeong, SH; Kim, SK; Lee, D, 2018
)
0.48
" Adverse events (AEs) were monitored throughout the study."( Efficacy and Safety of Estradiol Valerate/Dienogest for the Management of Heavy Menstrual Bleeding: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Clinical Trial.
Jaisamrarn, U; Lu, D; Parke, S; Suturina, L; Yu, Q; Zhou, Y, 2018
)
0.48
"EV/DNG may be a safe and effective option in the treatment of HMB in Asian and non-Asian women who desire contraception."( Efficacy and Safety of Estradiol Valerate/Dienogest for the Management of Heavy Menstrual Bleeding: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Clinical Trial.
Jaisamrarn, U; Lu, D; Parke, S; Suturina, L; Yu, Q; Zhou, Y, 2018
)
0.48
" Adverse events including bleeding disturbances and depressive symptoms were recorded."( Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice.
Römer, T, 2018
)
0.48
" Dienogest was well tolerated and adverse effects were clinically managed."( Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice.
Römer, T, 2018
)
0.48
" Single oral doses of 11β-MNTDC were well tolerated without serious adverse events."( Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men.
Amory, JK; Anawalt, BD; Bai, F; Blithe, DL; Bremner, WJ; Hull, L; Kim, K; Lee, MS; Liu, PY; Page, ST; Pak, Y; Parman, T; Swerdloff, RS; Thirumalai, A; Wang, C; Wu, S; Yuen, F, 2019
)
0.51
"A single, oral dose of 11β-MNTDC up to 800 mg administered with food is safe and well tolerated in healthy men."( Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men.
Amory, JK; Anawalt, BD; Bai, F; Blithe, DL; Bremner, WJ; Hull, L; Kim, K; Lee, MS; Liu, PY; Page, ST; Pak, Y; Parman, T; Swerdloff, RS; Thirumalai, A; Wang, C; Wu, S; Yuen, F, 2019
)
0.51
" Both clinical findings and laboratory findings are correlated and highly support the use of ND in burns as new effective and safe long-lasting indication."( Nandrolone decanoate safely combats catabolism in burned patients: A new potential indication after recall.
Ali, T; Ali, YH, 2022
)
2.16
" Study proposes that nandrolone decanoate could be used in safe and effective way to combat hypercatabolic impact in burn injury."( Nandrolone decanoate safely combats catabolism in burned patients: A new potential indication after recall.
Ali, T; Ali, YH, 2022
)
2.48
" Our research was directed to assess the toxic effects of anabolic steroids on cardiac and skeletal muscles in male albino rats and to evaluate the potential ameliorative effects of fenugreek seeds extract and silymarin."( The toxic effects of anabolic steroids "nandrolone decanoate" on cardiac and skeletal muscles with the potential ameliorative effects of silymarin and fenugreek seeds extract in adult male albino rats.
Abdelmenem, A; Alim, MAA; Ghaleb, SS; Hassan, DAE; Nabil, S; Zaki, AR, 2023
)
1.18
"The anabolic steroids toxic effects on rats showed a significant decrease in serum High Density Lipoprotein (HDL) level and increase in cholesterol, triglycerides, and Low-Density Lipoprotein (LDL) levels."( The toxic effects of anabolic steroids "nandrolone decanoate" on cardiac and skeletal muscles with the potential ameliorative effects of silymarin and fenugreek seeds extract in adult male albino rats.
Abdelmenem, A; Alim, MAA; Ghaleb, SS; Hassan, DAE; Nabil, S; Zaki, AR, 2023
)
1.18
"Anabolic steroids have a toxic effect on the cardiac and skeletal muscles of albino rats with improvement by treatment with fenugreek seeds extract and silymarin."( The toxic effects of anabolic steroids "nandrolone decanoate" on cardiac and skeletal muscles with the potential ameliorative effects of silymarin and fenugreek seeds extract in adult male albino rats.
Abdelmenem, A; Alim, MAA; Ghaleb, SS; Hassan, DAE; Nabil, S; Zaki, AR, 2023
)
1.18

Pharmacokinetics

ExcerptReferenceRelevance
" From these data basic pharmacokinetic parameters were calculated."( Pharmacokinetics of the progestin dienogest (STS 557) in rabbits.
Hillesheim, HG; Hobe, G; Ritter, P; Valentin, U, 1989
)
0.28
" The serum levels of nandrolone (19-nortestosterone) were determined by radioimmunoassay and used to estimate pharmacokinetic parameters."( Pharmacokinetic parameters of nandrolone (19-nortestosterone) after intramuscular administration of nandrolone decanoate (Deca-Durabolin) to healthy volunteers.
Bosch, AM; Donker, CW; Wijnand, HP, 1985
)
0.88
" The method was used to measure serum concentrations of NT, T and DHT in a pharmacokinetic study and in a clinical trial for male fertility control."( Pharmacokinetics of 19-nortestosterone esters in normal men.
Belkien, L; Gunnarsson, PO; Hano, R; Nieschlag, E; Schürmeyer, T, 1985
)
0.27
" Following the demonstration of the safety of MENT Ac in subchronic toxicity studies in rats and rabbits, a pharmacokinetic study was performed in men."( Pharmacokinetics of 7 alpha-methyl-19-nortestosterone in men and cynomolgus monkeys.
Aguillaume, C; Bardin, CW; Kumar, N; Lähteenmaki, P; Sundaram, K; Suvisaari, J; Tsong, YY,
)
0.13
" Thus, the stronger oral activity of dienogest could be explained simply by its in vitro potency on PR and its oral pharmacokinetic profile."( Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile.
Imada, K; Kami, H; Kato, S; Mita, S; Mizuguchi, K; Sasagawa, S; Shimizu, Y; Takeuchi, T, 2008
)
0.35
" This pharmacodynamic study investigated the ovulation-inhibiting effects of dienogest monotherapy in healthy women."( Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women.
Duijkers, I; Faustmann, T; Klein, S; Klipping, C; Remmers, A; Schuett, B; Zurth, C, 2012
)
0.38
"14, and the terminal half-life remained unchanged when single dosing and multiple dosing were compared."( Pharmacokinetic study of single and multiple oral administrations of 2 mg dienogest in healthy Korean women.
Jang, IJ; Lee, S; Lim, KS; Park, JS; Shin, D; Shin, SG; Yu, KS, 2013
)
0.39
"The present study described the single- and multiple-dose pharmacokinetic profiles of dienogest in Korean women and showed linear pharmacokinetics of dienogest at steady state."( Pharmacokinetic study of single and multiple oral administrations of 2 mg dienogest in healthy Korean women.
Jang, IJ; Lee, S; Lim, KS; Park, JS; Shin, D; Shin, SG; Yu, KS, 2013
)
0.39

Compound-Compound Interactions

ExcerptReferenceRelevance
" We investigated the effect of this new sexual hormone alone and in combination with ethynylestradiol on the elimination of both testdrugs."( [Effect of a new gestagen--dienogest--and its combination with ethinyl estradiol on the activity of biotransformation reactions].
Balogh, A; Hoffmann, A; Klinger, G; Liewald, S; Liewald, T; Schröder, S; Splinter, FC, 1990
)
0.28
"Fifty RA patients receiving prednisolone and prednisolone combined with retabolil were examined."( [Experimental substantiation of the treatment of patients with rheumatoid arthritis with prednisolone and its combination with retabolil (clinico-experimental study)].
Bagirova, VV; Iaglinskiĭ, VA; Kriukov, AP, 1986
)
0.27
"The authors report on the experience with amino acid drugs ( alvesin -new, aminon ) used in combination with anabolic steroids (retabolil) in patients with acute myocardial infarctions."( [Clinical efficacy of using amino acids in combination with anabolic steroids for the purpose of limiting the size of a myocardial infarct].
Leshchinskiĭ, LA; Vtorov, AE, 1984
)
0.27
" Therefore, we conducted a 6-month, prospective, randomized trial comparing low-dose rHuEPO alone and in combination with androgens for the treatment of the anemia of end-stage renal failure."( A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients.
Buhsmer, JP; Burke, JF; Dunn, SR; Gaughan, WJ; Liss, KA; Mangold, AM; Michael, B, 1997
)
0.3
" This study aimed to investigate MENT implants in combination with etonogestrel on spermatogenesis, gonadotropins, and androgen-dependent tissues in comparison with a testosterone/etonogestrel regimen."( 7alpha-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men.
Anderson, RA; Baird, DT; Kumar, N; Ludlow, H; Walton, MJ,
)
0.13
"The aim of this study was to evaluate the expression of key genes responsible for tendon remodeling of the proximal and distal regions of calcaneal tendon (CT), intermediate and distal region of superficial flexor tendon (SFT) and proximal, intermediate and distal region of deep flexor tendon (DFT) submitted to 7 weeks of jumping water load exercise in combination with AAS administration."( Gene expression in distinct regions of rat tendons in response to jump training combined with anabolic androgenic steroid administration.
Carvalho, HF; de Andrade Perez, SE; Durigan, JL; Heinemeier, KM; Kjaer, M; Marqueti, RC; Marqueti, Rde C; Schjerling, P; Selistre-de-Araujo, HS, 2012
)
0.38
" Herein, using transactivation assays, we examined the ability of MENT alone or combined with several 19-nor-derived synthetic progestins to activate androgen receptor (AR)-dependent gene transcription."( Comparison of 7α-methyl-19-nortestosterone effectiveness alone or combined with progestins on androgen receptor mediated-transactivation.
Chávez, B; Cooney, AJ; García-Becerra, R; Larrea, F; Noé, G; Ordaz-Rosado, D, 2012
)
0.38
" To address this question, we aimed to investigate the effects of high doses of nandrolone combined with strenuous resistance training (RT) on function and structure of thoracic aorta."( Nandrolone combined with strenuous resistance training reduces vascular nitric oxide bioavailability and impairs endothelium-dependent vasodilation.
Briet, L; Costa, R; Cunha, TS; das Neves, VJ; Franco, MDCP; Guzzoni, V; Marcondes, FK; Moura, MJCS; Novaes, PD; Oliveira, V, 2018
)
2.15

Bioavailability

Nandrolone decanoate injection was found to increase the bioavailability and peak levels of NO. NO production and bioavailability decreased in thoracic aorta of nandrol one-treated rats in relation to non-trained group.

ExcerptReferenceRelevance
" Following oral administration the high bioavailability of Dienogest which was already found in other animal species and in man could also be confirmed with rabbits."( Pharmacokinetics of the progestin dienogest (STS 557) in rabbits.
Hillesheim, HG; Hobe, G; Ritter, P; Valentin, U, 1989
)
0.28
" This suggests that, regardless of potential binding proteins, medroxyprogesterone acetate displays greater bioavailability than that of the other progestogens studied."( Comparison of in vivo bioavailability of progestational agents into the rat uterus and liver and the effect of plasma protein binding.
Matt, DW; Steingold, KA; Tedeschi, ML; Van Voorhis, B, 1989
)
0.28
" Bioavailability of orally administered STS 557 was found to be 80--90% in man and beagle dog, 70--80% in baboon and rat."( Studies on pharmacokinetics of STS 557 in animal species and man.
Carol, W; Chemnitius, KH; Claussen, C; Erdmann, A; Goncharov, NP; Hillesheim, HG; Hobe, G; Klinger, G; Komor, A; Ritter, P; Schumann, W; Wagner, H; Wehrberger, K; Wesemann, R, 1983
)
0.27
" After nandrolone decanoate injection, the highest bioavailability and peak nandrolone levels were observed with the 1-ml gluteal injection."( Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume.
Conway, AJ; Handelsman, DJ; Howe, C; Minto, CF; Wishart, S, 1997
)
1.02
" Since we anticipate using MENT acetate (MENT Ac) rather than MENT as the form of this androgen in humans, the bioavailability of MENT following the administration of MENT and MENT Ac was investigated in cynomolgus monkeys."( Pharmacokinetics of 7 alpha-methyl-19-nortestosterone in men and cynomolgus monkeys.
Aguillaume, C; Bardin, CW; Kumar, N; Lähteenmaki, P; Sundaram, K; Suvisaari, J; Tsong, YY,
)
0.13
"It was the aim of this study to investigate whether assessment of the metabolic stability of selected progestins of the 19-nortestosterone type in human microsomal liver preparations was a suitable approach to predict the oral bioavailability of these drugs in humans."( Predicting the oral bioavailability of 19-nortestosterone progestins in vivo from their metabolic stability in human liver microsomal preparations in vitro.
Gieschen, H; Kuhnz, W, 1998
)
0.3
" There are no data on oral bioavailability of free beta-NT from beta-NT esters."( Residues of nortestosterone esters at injection sites. Part 1. Oral bioavailability.
McCaughey, WJ; McEvoy, JD; McVeigh, CE, 1998
)
0.3
" In order to make sure about the adequacy of doses and bioavailability of drug, testes parameters were also considered."( Chronic administration of nandrolone decanoate does not increase the plasma homocysteine level of male rats.
Golbahar, J; Mirkhani, H; Shokri, S, 2005
)
0.63
"The contribution of lymphatic transport to the oral bioavailability of methylnortestosterone (M) after oral administration of the lipophilic prodrug methylnortestosterone undecanoate (MU) has been evaluated, and the sensitivity of lymphatic MU transport to lymphatic lipid transport has been investigated."( Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU.
Charman, WN; Edwards, GA; Faassen, WA; Nguyen, G; Porter, CJ; White, KL, 2009
)
0.35
" This may be due to a slower rate of absorption and/or a reduced diuresis, resulting in a longer period for the metabolites to accumulate in the urine."( Influence of delivery mode on the urinary excretion of nandrolone metabolites.
Dunster, PM; Grace, PB; Houghton, E; Judkins, C; Maughan, RJ; Watson, P, 2010
)
0.61
"Dienogest (DNG), a progestin of 19-nortestosterone derivative, has good oral bioavailability and is highly selective for progesterone receptors."( Dienogest: a new therapeutic agent for the treatment of endometriosis.
Harada, T; Taniguchi, F, 2010
)
0.36
" It has high oral bioavailability and a half-life suitable for once-daily administration."( Dienogest: a review of its use in the treatment of endometriosis.
McCormack, PL, 2010
)
0.36
" The absorption rate constant of compounds is found to be related to the logP of the solubilized prodrug."( Fundamental understanding of drug absorption from a parenteral oil depot.
Kalicharan, RW; Schot, P; Vromans, H, 2016
)
0.43
" NO production and bioavailability decreased in thoracic aorta of nandrolone-treated rats in relation to their matched non-trained group (NTN vs."( Nandrolone combined with strenuous resistance training reduces vascular nitric oxide bioavailability and impairs endothelium-dependent vasodilation.
Briet, L; Costa, R; Cunha, TS; das Neves, VJ; Franco, MDCP; Guzzoni, V; Marcondes, FK; Moura, MJCS; Novaes, PD; Oliveira, V, 2018
)
2.16
"11β-Methyl-19-nortestosterone-17β-dodecylcarbonate (11β-MNTDC) is an orally bioavailable prodrug of 11β-methyl-19-nortestosterone (11β-MNT) with androgenic and progestational activity."( Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men.
Amory, JK; Anawalt, BD; Bai, F; Blithe, DL; Bremner, WJ; Hull, L; Kim, K; Lee, MS; Liu, PY; Page, ST; Pak, Y; Parman, T; Swerdloff, RS; Thirumalai, A; Wang, C; Wu, S; Yuen, F, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Nandrolone phenylpropionate, an anabolic steroid, in bulk drug, in conventional parenteral dosage formulation and in prepared nanoparticle dosage form. The results attained show that pharmacological dosage of nandrol one, slowing cell growth, repressed mitochondrial respiration.

ExcerptRelevanceReference
" The dose-response curves of all the test agents expressed in terms of percentage inhibition were approximately parallel to each other."( Anti-androgen TSAA-291. I. Anti-androgenic effects of a new steroid TSAA-291 (16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one) and its derivatives.
Masaki, T; Masuoka, M; Nakayama, R; Shimamoto, K, 1979
)
0.26
" The classification of the anti-androgens, their indications, side-effects, dosage schemes and results of treatment are reviewed."( [Clinical aspects of the anti-androgens].
Holtzhausen, GH, 1979
)
0.26
" These effects might be obtained with a lower dosage of the drug."( Androgen trial in renal anaemia.
Gibbons, AR; Gyde, OH; Harris, BR; Naik, RB; Robinson, BH, 1978
)
0.26
" The 14C-drug was eliminated mostly as metabolites within 10 days after dosing with higher activities found in the feces than in urine."( Disposition and metabolism of 16 beta-ethyl-17 beta-hydroxy-4-estern-3-one (TSAA-291), a new antiandrogen, in rats.
Kanai, Y; Kondo, T; Tanayama, S; Yoshida, K, 1979
)
0.26
" The glucocorticoid effect on motoneuron outlasts the dosing period, suggesting an underlying alteration in the neuron."( Glucocorticoids and mammalian motor nerve excitability.
Baker, T; Okamoto, M; Riker, WF, 1975
)
0.25
" The rats were treated using a therapeutic dosage or a dosage that was five times the therapeutic level."( The effects of anabolic steroids on collagen synthesis in rat skeletal muscle and tendon. A preliminary report.
Karpakka, JA; Pesola, MK; Takala, TE,
)
0.13
" In addition, 5 body builders received the same dosage of nandrolone-decanoate or placebo, in a double blind cross-over design during two 8-week periods, interspersed by 12 weeks."( Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body builders.
Hartgens, F; Kuipers, H; Wijnen, JA; Willems, SM, 1991
)
0.53
" Knowing that the half-life for nandrolone decanoate in man is similar to that in rats, theoretical considerations are given with a number of dosing schemes."( Implications of basic pharmacology in the therapy with esters of nandrolone.
van der Vies, J, 1985
)
0.79
" If applicable, all anabolic agents were found to be present in a variety of esterified dosage forms."( [Anabolic steroid residues in administration sites in slaughtering cattle. October 1983 - January 1985].
Jansen, EH; Stephany, RW; van Blitterswijk, H, 1985
)
0.27
" Half of the compounds decreased uterine weight at lower doses but increased it at higher doses within the dosage range (1-4000 micrograms/day)."( Anti-ovulatory effects of some androgenic-myotrophic steroids in the pubertal rat.
Boris, A; Nelson, EW; Trmal, T, 1972
)
0.25
" Extensive testicular damage was caused by both ethynylestrenol and ethylestrenol, whereas only a 5 mg dosage of allylestrenol produced histological alteration of the testis."( Estrenols and male sex organs. I. Effect of a few structurally related 19-nortestosterone derivatives on sex organs of adult male albino rats.
Jogi, KV; Sarkar, SL, 1971
)
0.25
"A controlled, blind-labeled, dose-response field trial was conducted to evaluate the efficacy of mibolerone as a treatment for pseudopregnancy in the bitch."( Efficacy and dosage titration study of mibolerone for treatment of pseudopregnancy in the bitch.
Brown, JM, 1984
)
0.27
" This finding demonstrates that postcoital STS 557 in the chosen dosage does not suppress ovulation."( STS 557 as an interceptive in baboons.
Goncharov, NP; Komor, A; Oettel, M; Schubert, K, 1983
)
0.27
"Male hamsters of an inbred strain carrying a genetic trait for cardiomyopathy were dosed by sc injection weekly with an anabolic-androgenic steroid, nandrolone decanoate, beginning when 3 months old."( Nandrolone decanoate reduces the premature mortality of cardiomyopathic hamsters.
Davis, WM; Lin, TL; Long, SF, 1993
)
1.93
", reduction of bone resorption and/or stimulation of bone formation), the ultimate effect on mechanical properties, and the most effective dosage are not yet clear."( Mechanical properties, bone mineral content, and bone composition (collagen, osteocalcin, IGF-I) of the rat femur: influence of ovariectomy and nandrolone decanoate (anabolic steroid) treatment.
Aerssens, J; Dequeker, J; Geusens, P; Osman, AA; Schot, LP; Van Audekercke, R, 1993
)
0.49
" The authors reported that this study is the first to quantify the dose-response characteristics of individual AAS compounds with regard to these behavioral and endocrine measures."( Comparison of the effects of 17 alpha-methyltestosterone, methandrostenolone, and nandrolone decanoate on the sexual behavior of castrated male rats.
Clark, AS; Fast, AS, 1996
)
0.52
" In normal men, a single intravenous bolus of 500 micrograms of MENT led to peak serum MENT levels at 3 minutes after dosing (when the first samples were collected), followed by an exponential decline, reaching undetectable levels by 180 minutes."( Pharmacokinetics of 7 alpha-methyl-19-nortestosterone in men and cynomolgus monkeys.
Aguillaume, C; Bardin, CW; Kumar, N; Lähteenmaki, P; Sundaram, K; Suvisaari, J; Tsong, YY,
)
0.13
" dosage of 50 mg/kg, conjugates 1 and 2 induced strong tumor inhibition of Nobel Nb prostate carcinoma in rats, but also a marked loss of body weight."( Novel steroid-linked conjugates of 17 beta-[N-[N'-(2-chloroethyl)-N'-nitroso]carbamoyl]amino acids and their antineoplastic activity against Noble Nb prostate carcinoma model in rats.
Eisenbrand, G; Schneider, MR; Tang, W, 1998
)
0.3
" In castrated monkeys, dose-response relationships were generated for the effects of testosterone and MENT on gonadotropin levels, prostate growth, body weight, and lipid metabolism."( Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception.
Bardin, CW; Bremner, WJ; Cummings, DE; Kumar, N; Sundaram, K, 1998
)
0.3
" Furthermore, the histological changes observed in the seminiferous tubules in testes of STS 557--treated mice were not different in different dosage groups."( Effect of 17 alpha-cyanomethyl-17 beta-hydroxy-estra-4, 9-dien-3-one on reproductive organs of the male laboratory mouse.
Chakravarty, S; Singh, SK, 1998
)
0.3
" At a dosage of 80 mg twice daily, plasma testosterone levels are largely in the normal range, but plasma DHT tends to be elevated."( Androgen replacement therapy: present and future.
Bunck, MC; Gooren, LJ, 2004
)
0.32
" In order to evaluate the anabolic or toxic effects of the dosing regimens used, selected peripheral effects were monitored as well."( The effect of sub-chronic nandrolone decanoate treatment on dopaminergic and serotonergic neuronal systems in the brains of rats.
Ellermaa, S; Kankaanpää, A; Karila, T; Kurling, S; Seppälä, T, 2005
)
0.63
" Two days after the last training session, the animals were killed and blood samples for lipoprotein dosage were obtained."( Vascular sensitivity to phenylephrine in rats submitted to anaerobic training and nandrolone treatment.
Bernardes, CF; Cunha, TS; Marcondes, FK; Moura, MJ; Tanno, AP, 2005
)
0.55
" One means of improving user adherence with hormonal contraception is to minimize the dosing schedule."( A review of transdermal hormonal contraception : focus on the ethinylestradiol/norelgestromin contraceptive patch.
Graziottin, A, 2006
)
0.33
"If goals of future studies are to improve body composition, dosing of ND up to 200 mg/week in males and 50 mg/week in females should be investigated."( Nandrolone decanoate as anabolic therapy in chronic kidney disease: a randomized phase II dose-finding study.
Ahmed, W; Jibani, MM; Kumwenda, MJ; Lemmey, AB; Macdonald, JH; Marcora, SM, 2007
)
1.78
" The day after the last injection, the dose-response to ISO (1 x 10(-8), 5 x 10(-8) and 10(-7)M), was studied in isolated rat hearts harvested from unstressed animals (unstressed+vehicle (control) or unstressed+ND) or from stressed animals (stressed+vehicle or stressed+ND): acute stress protocol consisted in restrain for 1h immediately before sacrifice."( Nandrolone-pretreatment enhances cardiac beta(2)-adrenoceptor expression and reverses heart contractile down-regulation in the post-stress period of acute-stressed rats.
Abbadessa, G; Mancardi, D; Pagliaro, P; Penna, C; Racca, S; Spaccamiglio, A, 2007
)
1.78
" In an additional experiment, ovaries were excised 24 h after dosing for histological examinations."( Dienogest, a selective progestin, reduces plasma estradiol level through induction of apoptosis of granulosa cells in the ovarian dominant follicle without follicle-stimulating hormone suppression in monkeys.
Imada, K; Mizuguchi, K; Nagaoka, T; Sasagawa, S; Shimizu, Y; Tokado, H, 2008
)
0.35
"Growth-promoting agents are illicitly used during animal rearing processes and the detection of their use is limited by new compounds and dosing practices that limit the efficiency of current testing which is based on residue analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and gas chromatography-mass spectrometry (GC-MS) methodology."( Biosensor-based detection of reduced sex hormone-binding globulin binding capacities in response to growth-promoter administrations.
Bergwerff, AA; Elliott, CT; Luppa, PB; Mooney, MH; van Meeuwen, JA, 2009
)
0.35
"To evaluate the pharmacokinetics of a combined oral contraceptive (OC) containing oestradiol valerate/dienogest (E2V/DNG) administered according to a four-phasic dosing regimen with an oestrogen step-down and a progestin step-up over 26 days of active treatment."( Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest.
Blode, H; Lu, M; Morrison, D; Uddin, A; Zeiler, B; Zeun, S, 2009
)
0.35
" M and MU were administered intravenously and orally to greyhound dogs to determine absolute bioavailability after oral dosing of MU."( Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU.
Charman, WN; Edwards, GA; Faassen, WA; Nguyen, G; Porter, CJ; White, KL, 2009
)
0.35
"This study compared the bleeding pattern, cycle control and safety of an oral contraceptive (OC) comprising estradiol valerate/dienogest (E2V/DNG; administered using a dynamic dosing regimen) with a monophasic OC containing ethinyl estradiol 20 mcg/levonorgestrel 100 mcg (EE/LNG)."( Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
Ahrendt, HJ; Makalová, D; Mansour, D; Mellinger, U; Parke, S, 2009
)
0.35
"The objective of this study was to determine whether the rabbit was a suitable model to test new synthetic androgens for potential liver toxicity within a short dosing interval."( Effects of synthetic androgens on liver function using the rabbit as a model.
Attardi, BJ; Hild, SA; Koduri, S; Reel, JR; Till, BA,
)
0.13
" However, it has a complex dosage regimen, and has its own missed-pill guidance which differs substantially from that for other pills."( What role for Qlaira in contraception?
, 2010
)
0.36
"Dienogest (Visanne®) is a synthetic oral progestogen with unique pharmacological properties that is indicated at a dosage of 2 mg/day for the treatment of endometriosis."( Dienogest: a review of its use in the treatment of endometriosis.
McCormack, PL, 2010
)
0.36
"0 mg/kg/d)-treated rabbits during the 12-week dosing interval, but were comparable to pretreatment levels after cessation of dosing."( Development of dimethandrolone 17beta-undecanoate (DMAU) as an oral male hormonal contraceptive: induction of infertility and recovery of fertility in adult male rabbits.
Attardi, BJ; Engbring, JA; Gropp, D; Hild, SA,
)
0.13
"This study describes development and subsequent validation of a reversed phase high performance liquid chromatographic (RP-HPLC) method for the estimation of nandrolone phenylpropionate, an anabolic steroid, in bulk drug, in conventional parenteral dosage formulation and in prepared nanoparticle dosage form."( Development and validation of RP HPLC method to determine nandrolone phenylpropionate in different pharmaceutical formulations.
Chakrabarty, US; Choudhury, H; Das, A; Dey, G; Mukherjee, J; Pal, TK; Sahoo, BK,
)
0.57
" The recovery period, which was needed for the DA system to return back to the basic level, was fairly long compared to the dosing period of the steroid."( Subchronic steroid administration induces long lasting changes in neurochemical and behavioral response to cocaine in rats.
Kailanto, S; Kankaanpää, A; Seppälä, T, 2011
)
0.37
" Furthermore, the dynamic dosing regimen requires relatively complex instructions for users who miss pills."( Estradiol valerate and dienogest: a novel four-phasic oral contraceptive pill effective for pregnancy prevention and treatment of heavy menstrual bleeding.
Jensen, JT; Micks, E, 2011
)
0.37
" Estradiol valerate/dienogest differs from other oral contraceptives in that it necessitates more stringent dosing guidelines for maximum contraceptive efficacy."( Estradiol valerate/dienogest: a novel oral contraceptive.
Rose, R; Whalen, KL, 2011
)
0.37
"Estradiol valerate/dienogest (E2V/DNG) is a combined oral contraceptive (COC) with 2 new hormonal entities and a unique 4-phasic dosing regimen indicated for women to prevent pregnancy."( Estradiol valerate/dienogest: a novel combined oral contraceptive.
Borgelt, LM; Martell, CW, 2012
)
0.38
" Klaira® (E2V/DNG) combines the use of natural estradiol in a dynamic dosing regimen with a progestin very similar to natural progesterone but with very potent antiproliferative action at the endometrial level."( [Association of E2v/DNG as contraceptive choice for a better quality of life of women].
Nappi, RE, 2012
)
0.38
"14, and the terminal half-life remained unchanged when single dosing and multiple dosing were compared."( Pharmacokinetic study of single and multiple oral administrations of 2 mg dienogest in healthy Korean women.
Jang, IJ; Lee, S; Lim, KS; Park, JS; Shin, D; Shin, SG; Yu, KS, 2013
)
0.39
" A clear dose-response relationship was observed between groups."( Nandrolone decanoate induces genetic damage in multiple organs of rats.
de Moura, CF; Fernandes, KP; Fernandes, KR; Ferrari, RA; Pozzi, R; Renno, AC; Ribeiro, DA, 2013
)
1.83
" Recently, the oral combination contraceptive (COC) containing estradiol valerate (E2V) in combination with dienogest (DNG) was developed in a new estrogen step-down, progesterone step-up dosing strategy (Qlaira, Bayer Healthcare Pharmaceuticals)."( Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism.
De Leo, V; Di Sabatino, A; Fruzzetti, F; Morgante, G; Musacchio, MC; Scolaro, V, 2013
)
0.39
"The objective of this multicentre, randomised, double-blind study was to compare a combined oral contraceptive (COC) containing oestradiol valerate/dienogest (E2V/DNG) administered in a dynamic dosing regimen with a monophasic COC containing ethinyloestradiol/levonorgestrel (EE/LNG), with regard to their ability to reduce the frequency and intensity of headache and pelvic pain in women with hormone withdrawal-associated symptoms (HWAS)."( Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study.
Macìas, G; Mellinger, U; Merki-Feld, GS; Parke, S; Serrani, M, 2013
)
0.39
"Women would prefer more natural hormonal contraception, with high reliability, good tolerability, a simple dosing schedule and possibly some health advantages."( Contraception containing estradiol valerate and dienogest--advantages, adherence and user satisfaction.
Graziottin, A, 2014
)
0.4
"The new pill containing estradiol valerate and dienogest may satisfy women's need for: a more natural hormonal contraceptive with a low hormone dosage, high reliability and good tolerability; a simple dosing schedule (one pill per day for 28 days); a positive cosmetic effect on the skin; lighter and shorter withdrawal bleeding, improved anaemia, less fatigue and higher vital energy; reduced dysmenorrhoea and a dramatic reduction in all symptoms thanks to a shorter Hormone Free Interval (HFI) of just two days."( Contraception containing estradiol valerate and dienogest--advantages, adherence and user satisfaction.
Graziottin, A, 2014
)
0.4
"The pill containing estradiol valerate and dienogest is a contraceptive option that may satisfy women's demands for a more natural contraceptive while offering high reliability, good tolerability, a simple dosing schedule, lighter and shorter withdrawal bleeding, improved anaemia and a reduction in cycle-related symptoms thanks to a shorter Hormone Free Interval, and improved sexuality and general well-being."( Contraception containing estradiol valerate and dienogest--advantages, adherence and user satisfaction.
Graziottin, A, 2014
)
0.4
" Supra-physiological dosage of ND negatively reverses the effects of exercise on the cardiac muscle expression of sarcolemmal, but not mitochondrial, K(ATP) channel subunits."( Nandrolone decanoate negatively reverses the beneficial effects of exercise on cardiac muscle via sarcolemmal, but not mitochondrial K(ATP) channel.
Bayat, G; Goudarzvand, M; Hajizadeh, S; Javan, M; Khalili, A; Safari, F; Salimi, M; Shokri, S, 2016
)
1.88
" A marketed dosing regimen of estradiol valerate with dienogest (E2V/DNG) served as reference since it contains (like E4) a natural oestrogen."( Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA).
Apter, D; Beekman, L; Coelingh Bennink, HJ; Foidart, JM; Maillard, C; Mawet, M; Zimmerman, Y, 2016
)
0.43
" DMAU was dosed orally in healthy adult male volunteers at two academic medical centers."( Comparison of the single dose pharmacokinetics, pharmacodynamics, and safety of two novel oral formulations of dimethandrolone undecanoate (DMAU): a potential oral, male contraceptive.
Amory, JK; Ayoub, R; Blithe, D; Bremner, WJ; Chao, JH; Christy, A; Hull, L; Leung, A; Liu, PY; Page, ST; Swerdloff, RS; Wang, C, 2017
)
0.46
" The results attained show that pharmacological dosage of nandrolone, slowing cell growth, repressed mitochondrial respiration, inhibited the respiratory chain complexes I and III and enhanced mitochondrial reactive oxygen species (ROS) production."( Nandrolone induces a stem cell-like phenotype in human hepatocarcinoma-derived cell line inhibiting mitochondrial respiratory activity.
Agriesti, F; Capitanio, N; Cela, O; Laurenzana, I; Mazzoccoli, C; Pacelli, C; Piccoli, C; Pomara, C; Ruggieri, V; Salerno, M; Sani, G; Scrima, R; Sessa, F; Tataranni, T, 2020
)
2.25
" These discrepancies might be due to the differences in sex, age, dosage and treatment duration, and administration route."( Association between nandrolone and behavioral alterations: A systematic review of preclinical studies.
Javanmardy, S; Khazaei, MR; Niromand, E; Salimi, Z; Zarei, F, 2021
)
0.94
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
17beta-hydroxy steroidA 17-hydroxy steroid in which the hydroxy group at position 17 has a beta-configuration.
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
anabolic androgenic steroidA steroid hormone related to the hormone testosterone. It increases protein synthesis within cells, which results in the buildup of cellular tissue (anabolism), especially in muscles. It also has androgenic and virilizing properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency89.12510.100020.879379.4328AID588453
SMAD family member 2Homo sapiens (human)Potency13.67230.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency13.67230.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency28.67000.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency32.98610.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency5.02260.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency3.57130.000657.913322,387.1992AID1259377; AID1259378; AID1259394
progesterone receptorHomo sapiens (human)Potency13.73810.000417.946075.1148AID1346784; AID1346795; AID1347036
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency4.70530.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency34.69270.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency29.36210.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency1.36780.000229.305416,493.5996AID1259383; AID743069; AID743075; AID743077; AID743078; AID743079
glucocerebrosidaseHomo sapiens (human)Potency11.22020.01268.156944.6684AID2101
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency21.66920.001024.504861.6448AID743215
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency27.279919.739145.978464.9432AID1159509
Histone H2A.xCricetulus griseus (Chinese hamster)Potency63.09560.039147.5451146.8240AID1224845; AID1224896
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency125.89200.010039.53711,122.0200AID1479
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency23.30110.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency30.30000.000627.21521,122.0200AID743202; AID743219
gemininHomo sapiens (human)Potency0.07310.004611.374133.4983AID624297
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency7.94336.309660.2008112.2020AID720707
Interferon betaHomo sapiens (human)Potency9.38350.00339.158239.8107AID1347407
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)35.10000.21005.553710.0000AID386625
Corticosteroid-binding globulinHomo sapiens (human)Ki0.72440.01323.248110.0000AID51055
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00310.00101.979414.1600AID625228
Androgen receptorRattus norvegicus (Norway rat)Ki0.00210.00031.21858.9270AID625228
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)IC50 (µMol)35.10002.03005.53139.9000AID386625
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)IC50 (µMol)120.00000.00051.89099.5000AID162967
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)IC50 (µMol)120.00000.06503.12999.5000AID162967
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)IC50 (µMol)120.00000.02603.56669.5000AID162967
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)IC50 (µMol)120.00000.02103.58609.5000AID162967
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sex hormone-binding globulinHomo sapiens (human)Kd0.50120.00020.34964.7863AID318680
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (107)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
glucocorticoid metabolic processCorticosteroid-binding globulinHomo sapiens (human)
negative regulation of endopeptidase activityCorticosteroid-binding globulinHomo sapiens (human)
glucose metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
cell population proliferation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stress[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
regulation of acetyl-CoA biosynthetic process from pyruvate[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
regulation of glucose metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
hypoxia-inducible factor-1alpha signaling pathway[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
protein phosphorylation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
glucose metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
regulation of gluconeogenesis[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
regulation of pH[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
insulin receptor signaling pathway[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
regulation of acetyl-CoA biosynthetic process from pyruvate[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
regulation of cellular ketone metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
regulation of glucose metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
cellular response to nutrient[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
cellular response to reactive oxygen species[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
glucose homeostasis[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
regulation of calcium-mediated signaling[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
protein phosphorylation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
regulation of acetyl-CoA biosynthetic process from pyruvate[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
regulation of glucose metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
peptidyl-serine phosphorylation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathway[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
cellular response to fatty acid[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
hypoxia-inducible factor-1alpha signaling pathway[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
regulation of reactive oxygen species metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
protein phosphorylation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
regulation of pH[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
insulin receptor signaling pathway[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
cellular response to starvation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
regulation of acetyl-CoA biosynthetic process from pyruvate[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
regulation of cellular ketone metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
regulation of glucose metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
regulation of fatty acid biosynthetic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
glucose homeostasis[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
response to starvation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
regulation of bone resorption[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
regulation of fatty acid oxidation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
cellular response to fatty acid[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
reactive oxygen species metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
negative regulation of anoikis[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
protein phosphorylation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
androgen bindingSex hormone-binding globulinHomo sapiens (human)
protein bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingCorticosteroid-binding globulinHomo sapiens (human)
serine-type endopeptidase inhibitor activityCorticosteroid-binding globulinHomo sapiens (human)
protein kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
pyruvate dehydrogenase (acetyl-transferring) kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
protein binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
ATP binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
protein kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
pyruvate dehydrogenase (acetyl-transferring) kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
protein binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
ATP binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
protein homodimerization activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
protein kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
protein serine/threonine kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
pyruvate dehydrogenase (acetyl-transferring) kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
protein binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
ATP binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
protein kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
pyruvate dehydrogenase (acetyl-transferring) kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
protein binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
ATP binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
extracellular regionSex hormone-binding globulinHomo sapiens (human)
extracellular exosomeSex hormone-binding globulinHomo sapiens (human)
extracellular regionCorticosteroid-binding globulinHomo sapiens (human)
extracellular spaceCorticosteroid-binding globulinHomo sapiens (human)
extracellular exosomeCorticosteroid-binding globulinHomo sapiens (human)
extracellular spaceCorticosteroid-binding globulinHomo sapiens (human)
mitochondrial matrix[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
mitochondrion[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
nucleoplasm[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
mitochondrion[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
mitochondrial matrix[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
cytosol[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
pyruvate dehydrogenase complex[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
mitochondrion[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
nucleolus[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
mitochondrion[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
mitochondrial matrix[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
mitochondrion[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
mitochondrial matrix[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
mitochondrion[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (123)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1150122Relative binding affinity to sheep progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID162457Displacement of [3H]R5020 from rat progesterone receptor(PgR)1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography.
AID162435Relative binding affinity for progesterone receptor(PgR) in human T47D cells1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A potential radioiodinated ligand for androgen receptor: 7 alpha-methyl-17 alpha-(2'-(E)-iodovinyl)-19-nortestosterone.
AID39323Relative binding affinity against rat ventral prostate androgen receptor using competition assay after 18 hours.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiandrogenic steroidal sulfonylpyrazoles.
AID226306Nonspecific binding (NSB) (R1881 = 1.00) calculated using an empirically derived relationship1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution.
AID126441Relative binding affinity for the mineralocorticoid receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1150121Relative binding affinity to human progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID51054Binding affinity for corticosteroid binding globulin is expressed as log(1/k)1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID69853Relative binding affinity against Estrogen receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID212922Relative binding affinity to the testosterone receptor.1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores.
AID51059Binding affinity to corticosteroid binding globulin1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID38686In vivo relative Androgenic activity in Male Sprague-Dawley rats1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Aldosterone antagonists. 2. Synthesis and biological activities of 11,12-dehydropregnane derivatives.
AID39152Relative binding affinity for androgen receptor (AR) in human MCF-7 cells1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A potential radioiodinated ligand for androgen receptor: 7 alpha-methyl-17 alpha-(2'-(E)-iodovinyl)-19-nortestosterone.
AID162465Relative binding affinity (RBA) for Progesterone receptor in competitive radiometric assay1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution.
AID203784Displacement of [3H]estradiol from human Sex steroid binding protein (SBP)1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID39318Relative binding affinity for androgen receptor (AR) in rat uterus1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A potential radioiodinated ligand for androgen receptor: 7 alpha-methyl-17 alpha-(2'-(E)-iodovinyl)-19-nortestosterone.
AID51048In silico binding affinity to human corticosteriod binding globulin1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.
AID39316Relative binding affinity against Androgen Receptor in Male Sprague-Dawley rats1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Aldosterone antagonists. 2. Synthesis and biological activities of 11,12-dehydropregnane derivatives.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID39454Relative binding affinity against androgen receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID386625Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID19824Partition coefficient (logP)1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution.
AID51055Binding affinity to human CBG receptor (corticosteroid-binding globulins)2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
Comparative molecular active site analysis (CoMASA). 1. An approach to rapid evaluation of 3D QSAR.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID51056Binding affinity to the corticosteroid-binding globulin (CBG) receptor.2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID39321Relative binding affinity (RBA) against androgen receptor (AR) using [3H]R-1881 as competitive radioligand.1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1150123Relative binding affinity to rabbit progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID90951In vitro effective concentration in normal human dermal fibroblasts; No data1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID74389Relative binding affinity against glucocorticoid receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID51049Binding affinity against corticosteroid-binding globulin1993Journal of medicinal chemistry, Feb-19, Volume: 36, Issue:4
Structure-activity relationships from molecular similarity matrices.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID51052In silico binding affinity to corticosteroid binding globulin (CBG)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. Method and validations.
AID39322Relative binding affinity against rat ventral prostate androgen receptor using competition assay after 1 hour.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiandrogenic steroidal sulfonylpyrazoles.
AID162967In vitro inhibitory activity against pyruvate dehydrogenase kinase was determined1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID51062In silico steroid binding affinity to transport protein corticosteroid binding globulin1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1150124Relative binding affinity to guinea pig progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID162462Relative binding affinity to the progesterone receptor.1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID51053Compound was evaluated for its binding affinity towards the human corticosteroid binding globulin1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Self-organizing molecular field analysis: a tool for structure-activity studies.
AID126436Displacement of [3H]aldosterone from rat Mineralocorticoid receptor1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography.
AID203786Relative binding affinity (RBA) for Sex steroid binding protein in competitive radiometric assay1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID51058Binding affinity towards corticosteroid-binding globulin (CBG)2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID162617Relative binding affinity against progestin receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID227714Binding selectivity index (BSI) as ratio of RBA for androgen receptor to non-specific binding of R18811995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID318680Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID39308Relative binding affinity (RBA) for Androgen receptor in competitive radiometric assay1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,797)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901381 (49.37)18.7374
1990's380 (13.59)18.2507
2000's445 (15.91)29.6817
2010's477 (17.05)24.3611
2020's114 (4.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 90.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index90.84 (24.57)
Research Supply Index8.10 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index170.47 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (90.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials314 (10.48%)5.53%
Reviews147 (4.91%)6.00%
Case Studies111 (3.71%)4.05%
Observational15 (0.50%)0.25%
Other2,408 (80.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (23)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Dienogest and Dienogest Plus Estradiol Valerate on Ovarian Reserve and Endometrioma Size [NCT03789123]Phase 4710 participants (Anticipated)Interventional2019-01-01Recruiting
Open-label, Randomized, Cross-over Study to Investigate the Bioequivalence of Estradiol Valerate (EV), Dienogest (DNG) and Levomefolate Calcium After Single Oral Administration of a Tablet Formulation Containing 2 mg Estradiol Valerate and 3 mg Dienogest [NCT00941057]Phase 143 participants (Actual)Interventional2009-09-30Completed
Bioavailability of a Formulation of Estradiol Valerate and Dienogest 2 mg/2 mg Coated Tablets With Regards to the Marketed Reference Product [NCT05332106]Phase 110 participants (Actual)Interventional2022-03-12Completed
The Effect of Nandrolone Decanoate Injection and Leucine Supplementation on Muscle Loss [NCT02376309]30 participants (Actual)Interventional2015-08-31Completed
Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Nandrolone Decanoate Therapy and Therapy With Complex Physiotherapy and Diet in the Treatment of Sarcopenia [NCT05978206]Phase 2168 participants (Anticipated)Interventional2023-08-10Recruiting
Preliminary Effect and Safety of Physiotherapy With Strength Training and Protein-rich Nutritional Supplement in Combination With Anabolic Steroids in Cross-continuum Rehabilitation of Patients With Hip Fracture - a Randomized Controlled Pilot Trial. (The [NCT03545347]Phase 229 participants (Actual)Interventional2018-09-03Completed
A Double-blind, Randomized, Dose-controlled Study to Evaluate Pharmacodynamic Properties of Four Oral Doses of Dienogest (DNG) in 100 Healthy Young Female Volunteers Over a Period of Two Cycles up to a Maximum of 72 Days [NCT00754871]Phase 1102 participants (Actual)Interventional2008-09-30Completed
Bioavailability of a Formulation of Dienogest 2.0 mg Coated Tablets With Regards to the Marketed Reference Product [NCT04230083]Phase 130 participants (Actual)Interventional2019-12-07Completed
Single Dose, Dose-Ranging Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men [NCT02754687]Phase 112 participants (Actual)Interventional2016-04-30Active, not recruiting
The Efficacy of Anabolic Steroids for the Nutritional Rehabilitation of Critically Ill Patients [NCT00242463]Phase 220 participants (Anticipated)Interventional2005-10-31Terminated(stopped due to drug no longer available in canada)
Assessment of Mechanisms of Improved Wound Healing of Anabolic Agents and Diet in Severely Burned Patients [NCT00673309]Phase 2/Phase 3644 participants (Actual)Interventional2000-07-31Completed
Characterisation of Relative Bioavailability and Assessment of Bioequivalence of a Newly Developed Ethinylestradiol/Dienogest IR Formulation in Comparison With a Marketed Reference Product (Valette®) [NCT01600274]20 participants (Actual)Interventional2010-01-31Completed
Assessment of the Treatment of the Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation [NCT00675714]Phase 2/Phase 31,126 participants (Actual)Interventional2004-01-31Terminated(stopped due to At the request of the study site, this study has been closed and access to study-related data is unavailable. We are unable to submit the results-data.)
Bioavailability of a Formulation of Dienogest and Ethinyl Estradiol 2.0 mg/0.03 mg Coated Tablets With Regards to the Marketed Reference Product [NCT04193852]Phase 110 participants (Actual)Interventional2019-11-09Completed
Synthetic vs Natural Estrogen in Combined Oral Contraception- Effect on Insulin Sensitivity, Coagulation, Inflammation and Endometrium - a Comparison With a Progestin-only Preparation. [NCT02352090]Phase 459 participants (Actual)Interventional2015-04-01Completed
Male Hormones for Telomere Related Diseases [NCT02055456]Phase 1/Phase 220 participants (Actual)Interventional2014-02-01Completed
[NCT00000597]Phase 30 participants Interventional1982-03-31Completed
Anabolic Steroids and Exercise in Hemodialysis Patients [NCT00250536]80 participants Interventional2000-03-31Completed
Comparative, Prospective, Multi-Center, Open, Randomized Study to Investigate Bleeding Patterns, Metabolic Effects, Contraceptive Efficacy, Acceptance, and Safety of an Oral Contraceptive Containing 0.03 mg Ethinylestradiol and 2 mg Dienogest, in Two Diff [NCT00302666]Phase 31,315 participants (Actual)Interventional2003-06-30Completed
Role of Anabolic Steroid and Propranolol in Paediatric Burn- A Randomized Controlled Trial [NCT05805553]114 participants (Anticipated)Interventional2020-12-01Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Trial of Nandrolone Decanoate in Women With HIV-Associated Weight Loss [NCT00000854]Phase 138 participants InterventionalCompleted
28-Day Repeat-Dose, Dose Escalation Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men [NCT03298373]Phase 143 participants (Actual)Interventional2017-11-09Active, not recruiting
Impact of the Use of Nandrolone on the Treatment of Malnutrition Induced by Cancer [NCT03263520]60 participants (Actual)Interventional2016-02-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02352090 (11) [back to overview]Anti Mullerian Hormone (AMH)
NCT02352090 (11) [back to overview]D-dimer
NCT02352090 (11) [back to overview]F1+2
NCT02352090 (11) [back to overview]Fasting Insulin
NCT02352090 (11) [back to overview]High-Density Lipoprotein (HDL)
NCT02352090 (11) [back to overview]High-sensitivity C Reactive Protein
NCT02352090 (11) [back to overview]Low-Density Lipoprotein (LDL)
NCT02352090 (11) [back to overview]Matsuda Index- Whole Body Insulin Sensitivity Index
NCT02352090 (11) [back to overview]Thrombin Generation, ETP Endogenous Thrombin Potential
NCT02352090 (11) [back to overview]Total Cholesterol
NCT02352090 (11) [back to overview]Triglyceride

Anti Mullerian Hormone (AMH)

Change in Serum concentrations of anti-mullerian hormone reflecting ovarian reserve from baseline to nine weeks (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionng/mL (Mean)
Synthetic Estrogen + Progestin-0.8
Natural Estrogen + Progestin-0.4
Progestin-Only0.07

[back to top]

D-dimer

Markers of coagulation activation (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionpercentage change from baseline (Mean)
Synthetic Estrogen + Progestin12.6
Natural Estrogen + Progestin2.4
Progestin-Only-1.6

[back to top]

F1+2

Change in plasma concentrations of F1+2 a marker of coagulation activation (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionpercentage change from baseline (Mean)
Synthetic Estrogen + Progestin24.1
Natural Estrogen + Progestin-5.5
Progestin-Only-8.5

[back to top]

Fasting Insulin

Mean change in fasting serum insulin from baseline to nine weeks (NCT02352090)
Timeframe: baseline and 9 weeks

InterventionmU/l (Mean)
Synthetic Estrogen + Progestin1.4
Natural Estrogen + Progestin1.02
Progestin-Only1.99

[back to top]

High-Density Lipoprotein (HDL)

Change in concentration of High-Density Lipoprotein HDL from baseline to nine weeks (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionmmol/L (Mean)
Synthetic Estrogen + Progestin0.20
Natural Estrogen + Progestin-0.02
Progestin-Only-0.02

[back to top]

High-sensitivity C Reactive Protein

Change in plasma concentrations of acute phase protein 'C reactive protein' (CRP), a marker of chronic inflammation. (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionmg/L (Mean)
Synthetic Estrogen + Progestin1.10
Natural Estrogen + Progestin-0.06
Progestin-Only0.13

[back to top]

Low-Density Lipoprotein (LDL)

Change in concentration of Low-Density Lipoprotein LDL from baseline to nine weeks (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionmmol/L (Mean)
Synthetic Estrogen + Progestin-0.16
Natural Estrogen + Progestin-0.14
Progestin-Only0.01

[back to top]

Matsuda Index- Whole Body Insulin Sensitivity Index

"Matsuda index is calculated from the standard 2h Oral Glucose Tolerance Test and corresponding insulin values.~Matsuda index = 10,000/square root of [fasting glucose x fasting insulin] x [mean glucose x mean insulin during OGTT]) The Matsuda index is correlated (r = 0.73) with the rate of whole-body glucose disposal during the euglycemic insulin clamp.~Matsuda index <2.5 is considered insulin resistant, higher values indicate less insulin resistance. A decrease in matsuda index over the study period would indicate decreased insulin sensitivity." (NCT02352090)
Timeframe: We calculated the change in Matsuda index from baseline to 9 weeks.

Interventionunits on a scale (Mean)
Synthetic Estrogen + Progestin-1.02
Natural Estrogen + Progestin-0.10
Progestin-Only-1.45

[back to top]

Thrombin Generation, ETP Endogenous Thrombin Potential

Change from baseline in thrombin generation, measured by thrombin generation assay-Calibrated automated thrombogram (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionpercentage change from baseline (Mean)
Synthetic Estrogen + Progestin63.9
Natural Estrogen + Progestin26.4
Progestin-Only7.1

[back to top]

Total Cholesterol

Change in concentrations of total cholesterol from baseline to nine weeks (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionmmol/L (Mean)
Synthetic Estrogen + Progestin0.10
Natural Estrogen + Progestin-0.16
Progestin-Only0.11

[back to top]

Triglyceride

Change in triglyceride concentrations from baseline to nine weeks (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionmmol/L (Mean)
Synthetic Estrogen + Progestin0.45
Natural Estrogen + Progestin0.18
Progestin-Only0.06

[back to top]